[ad_1]
New Delhi: Pharmaceutical Department has launched an online portal for one The 5,000 crore schemes say that there will be innovation in pharma and medical technology.
Promotion of research and innovation in PRIP, or Pharma Medtech sector, promises to submit applications to develop novel technologies in medicine, including medical devices and medicines to communicable, non-communicable diseases and drugs for rare diseases.
The government is concerned about the smaller levels of domestic R&D expenses compared to many other countries, despite being a global leader in India’s generic drug production.
While the US and China spend $ 60 billion and $ 20 billion on pharmaceutical R&D respectively, India costs only $ 3 billion.
Reduce a gap
The purpose of PRIP is to bridge this difference and promote the culture of research and innovation in the pharma and medtech industry.
The plan has two main components. First, strengthening research infrastructure: This includes the establishment of the Center for Excellence (COES) in the seven existing National Institute of Pharmaceutical Education and Research (Nipers).
Second, promoting research in Pharma and Medtech: This component provides direct financial assistance to companies and projects for both in-house R&D and educational cooperation. This includes six priority areas, including drug discovery and development, medical equipment, stem cell therapy, medications for rare diseases and treatment for drug resistant patients.
“With the PRIP portal, it is now simple to register and enhance its research and development capabilities for live, government pharma companies, medtech firms and even startups,” an official said.
As employed under the scheme, big companies can explore the above amount 125 crore while startups can secure The official said that on the basis of his milestone, 1 crore in a period of five years.
India’s drug market is a global force, which is worth $ 50 billion. While domestic consumption is $ 23.5 billion, exports contribute significantly by $ 26.5 billion. India is the third largest drug market in the world and ranks 14th from the price of production.
More than half of its exports reach highly developed markets such as the US, the European Union and Japan, whose quality has a high border.
Mankind Pharma promoter and CEO Sheetal Arora emphasized the transformational capacity of the Prip scheme.
Pharma Game Changer
“The new PRIP portal is a game-changer for Indian Pharma. This The investment of 5,000 crores is in the same way as we are on the verge of large scale growth. India already leads the world in generic drugs, which provides 20% of the global supply. But Prip helps us move towards innovation, possibly bringing another in another 17,000 crores for R&D by FY28. This will actually accelerate our competitive edge.
Time cannot be better. With several major drugs losing patent protection by 2030, now new molecules and companies investing in top-level research will be future leaders. The most exciting is that Prip supports both innovation and affordable healthcare. ,
Arora said that Prime supports both innovation and cheap healthcare. “It perfectly fit India’s goal of being a global innovation center, while also to make drugs accessible worldwide. Prip is not just about money; it is about making Indian pharma a strong, self -sufficient future to create a strong, self -sufficient future, where innovation benefits everyone,” he said.
The Indian Drug Manufacturers Association is actively encouraging its members to find out the opportunity, with the Prip scheme as a significant jump for research and development in the country.
[ad_2]
